Company intelligence / Profile preview
AB-BIOTICS
Barcelona/Cerdanyola del Vallès, Catalonia, Spainab-biotics.com ↗
- Ownership
- Private
- Employees
- ~100
- Development stage
- Other
01
Overview
AB-BIOTICS has conducted over 50 published clinical trials supporting the efficacy of its proprietary probiotic blends. Notably, its i3.1 blend demonstrated restoration of intestinal barrier function in IBS patients in vitro. The company’s portfolio includes clinically documented solutions for various health indications including infant colic and cardiometabolic health[2][4].
- Therapeutic areas
- GastroenterologyCardiovascularOther
- Modalities
- Live biotherapeutic product therapyMicrobial therapy
- Industry
- Biotech
02
Drug pipeline
31 assets30 more assets in the full pipeline.
03
Partnerships
Kaneka Corporation (distribution/expansion partner before acquisition)
Beyond the preview
Go deeper on AB-BIOTICS.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AB-BIOTICS.